Focal therapy for prostate cancer: current status and future perspectives

被引:0
作者
Miano, R. [1 ]
Asimakopoulos, A. D. [1 ]
Da Silva, R. D. [2 ]
Bove, P. [1 ]
Jones, S. J. [3 ]
De La Rosette, J. J. [4 ]
Kim, F. J. [2 ]
机构
[1] Univ Roma Tor Vergata, Dept Expt Med & Surg, Div Urol, I-00157 Rome, Italy
[2] Denver Hlth Med Ctr, Div Urol, Denver, CO USA
[3] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44106 USA
[4] Univ Amsterdam, Acad Med Ctr, Dept Urol, NL-1105 AZ Amsterdam, Netherlands
关键词
Prostatic neoplasms; Cryotherapy; High-intensity focused ultrasound ablation; Photochemotherapy; Electroporation; INTENSITY-FOCUSED ULTRASOUND; IRREVERSIBLE ELECTROPORATION; MALE LUMPECTOMY; RADICAL PROSTATECTOMY; PHOTODYNAMIC THERAPY; ACTIVE SURVEILLANCE; PATIENT SELECTION; INDEX LESION; CRYOABLATION; RISK;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Focal therapy is a relatively new and extremely attractive option of treatment for prostate cancer. It has been described as the "middle approach" between active surveillance and radical treatment, aiming to destroy the tumor itself or the region containing the tumor in order to preserve surrounding non-cancerous tissue. The goal is to maintain disease control at acceptable levels, while preserving erectile, urinary, and rectal function. While a lot of technologies have been described for delivering targeted therapy to the prostate, such as cryoablation, high intensity focused ultrasound, photodynamic therapy, irreversible electroporation and laser, the key point is the patient selection. Recent advances in mpMRI and the introduction of new biopsy techniques that use MR images as a guidance, have significantly improved localization of the tumor lesions and the detection rate, evolving prostate biopsy toward targeted rather than systematic biopsies. The future challenge to clinicians is to precisely risk-stratify patients to differentiate between those who would profit from focal treatment and who would not. Forthcoming research efforts should pursue to identify molecular, genetic, and imaging characteristics that distinguish aggressive prostate tumors from indolent lesions.
引用
收藏
页码:263 / 280
页数:18
相关论文
共 103 条
[1]   Focal Therapy for Localized Prostate Cancer: A Phase I/II Trial [J].
Ahmed, H. U. ;
Freeman, A. ;
Kirkham, A. ;
Sahu, M. ;
Scott, R. ;
Allen, C. ;
Van der Meulen, J. ;
Emberton, M. .
JOURNAL OF UROLOGY, 2011, 185 (04) :1246-1254
[2]   Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way? [J].
Ahmed, Hashim Uddin ;
Emberton, Mark .
WORLD JOURNAL OF UROLOGY, 2008, 26 (05) :457-467
[3]   Characterizing Clinically Significant Prostate Cancer Using Template Prostate Mapping Biopsy [J].
Ahmed, Hashim Uddin ;
Hu, Yipeng ;
Carter, Tim ;
Arumainayagam, Nimalan ;
Lecornet, Emilie ;
Freeman, Alex ;
Hawkes, David ;
Barratt, Dean C. ;
Emberton, Mark .
JOURNAL OF UROLOGY, 2011, 186 (02) :458-464
[4]   The Index Lesion and the Origin of Prostate Cancer [J].
Ahmed, Hashim Uddin .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (17) :1704-1706
[5]   INTERSTITIAL LASER PHOTOCOAGULATION FOR THE TREATMENT OF PROSTATIC-CANCER [J].
AMIN, Z ;
LEES, WR ;
BOWN, SG .
BRITISH JOURNAL OF RADIOLOGY, 1993, 66 (791) :1044-1047
[6]   Multifocal prostate cancer: biologic, prognostic, and therapeutic implications [J].
Andreoiu, Matei ;
Cheng, Liang .
HUMAN PATHOLOGY, 2010, 41 (06) :781-793
[7]  
[Anonymous], EUR UROL
[8]  
[Anonymous], WORLD J UROL
[9]  
[Anonymous], 2015, Eur Urol
[10]  
[Anonymous], PROSTATE CANC